Our results, obtained by monitoring MMP9 levels directly in the CMCs and plasma of PwCF undergoing Trikafta® therapy, provide additional information which is needed to validate MMP9 modulation as a biomarker of CF therapy efficacy. This evidence concerns the gene MMP9 and cystic fibrosis.